Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
In Vitro Diagnostics

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2060324

Cover Image

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2060324

Cardiac Marker Testing Market by Product, Biomarker (Troponin, CK-MB, BNP, hs-CRP, Myoglobin), Technology (Chemiluminescence, ELISA), Indication (MI, CHF, Atherosclerosis), Assay Format (Singleplex, Multiplex), Point of Testing - Global Forecast to 2031

PUBLISHED:
PAGES: 372 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (5-user License)
USD 6650
PDF (Corporate License)
USD 8150
PDF (Global License)
USD 10000

Add to Cart

Description

Table of Contents

List of Tables

The market for cardiac marker testing is valued at around USD 5.07 billion in 2025, USD 5.54 billion in 2026, and is forecast to reach USD 9.06 billion by 2031, representing a growth of 10.3%. The market is growing steadily, and the focus of hospitals and diagnostic laboratories is on early detection and accurate diagnosis of diseases, as well as on improving patient outcomes.

Scope of the Report
Years Considered for the Study2026-2031
Base Year2025
Forecast Period2026-2031
Units ConsideredValue (USD billion)
SegmentsProduct, Technology, Indication, Biomarker Type, Point Of Testing, Assay Format, End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and Middle East & Africa

The increasing complexity of cardiovascular diseases and the need for accurate diagnostic results and quality control by government agencies are also driving global demand for cardiac marker testing solutions.

Cardiac Marker Testing Market - IMG1

"The reagents & kits segment is predicted to showcase the highest CAGR during the forecast period."

The segment's growth is mainly driven by recurring demand for cardiac marker kits & reagents, which are required for every test. The prevalence rate for cardiovascular diseases is also on the rise, resulting in an increased hospitalization rate for such diseases. This, in turn, is fueling the demand for cardiac marker testing kits & reagents.

"The immunoassay segment is projected to hold the largest share of the cardiac marker testing market in 2026, by technology."

The immunoassay segment leads the market because hospital labs, reference labs, and academic institutions have adopted immunoassay-based testing, which offers higher sensitivity, specificity, and reliability for detecting cardiac biomarkers. It is the most preferred technology among healthcare providers for routine cardiac testing because immunoassay-based tests enable quick, accurate detection of myocardial infarction and related conditions. The consistent demand for immunoassay technology can be attributed to the rising incidence of cardiovascular diseases and the emphasis on early detection and management.

"Asia Pacific is expected to register the fastest growth rate in the cardiac marker testing market, by region."

The region is witnessing a growth spurt due to several key factors, including increased healthcare infrastructure, increased healthcare expenditure, and greater modernization of hospital and diagnostic facilities. In addition, rising cases of cardiovascular disease, increasing numbers of procedures performed, and growth in diagnostic labs and pharmaceutical companies are also driving growth in the cardiac marker testing market in the Asia Pacific region.

The break-up of the profile of primary participants in the cardiac marker testing market:

  • By Company Type: Tier 1 - 26%, Tier 2 - 44%, and Tier - 30%
  • By Designation: C-level - 30%, D-level - 34%, and Others - 36%
  • By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Middle East & Africa- 4%

The key players in the cardiac marker testing market are F.Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (US), Siemens Healthineers AG (Germany), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), Biomerieux SA (France), Becton, Dickinson and Company (US), Thermo Fisher Scientific (US), Diasorin SPA (Italy), Revvity (US), Tosho Corporation (Japan), and Quidel Corporation (US).

Research Coverage:

This research report categorizes the cardiac marker testing market by product (Reagents & Kits, Instruments), technology (Immunoassay, Clinical Chemistry), indication (Myocardial Infraction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, Ischemia), biomarker type (Troponin I & T, Creatinine Kinase-MB, Brain Natriuretic Peptide, Myoglobin, High-Sensitivity C-Reactive Protein, Homocysteine, Other Cardiac Biomarkers), point of testing (Lab Test, PoC Test), assay format (Singleplex Assay, Multiplex Assay), end user (Laboratory Testing Facilities, Academic Institutes, Point-of-Care Testing), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges, influencing the growth of the cardiac marker testing market. A detailed analysis of the key industry players has been conducted to provide insights into their business overviews, solutions, key strategies such as partnerships, collaborations, expansions, agreements, product launches, and recent developments in the cardiac marker testing market. This report provides a competitive analysis of emerging startups in the cardiac marker testing market ecosystem.

Reasons to buy this report:

The report will help market leaders and new entrants with information on the closest approximations of revenue numbers for the overall cardiac marker testing market and its subsegments. This report will help stakeholders understand the competitive landscape and gain deeper insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

  • Analysis of key drivers (rising prevalence of cardiovascular diseases, increasing geriatric population and subsequent rise in heart conditions worldwide, rising clinical studies for identification of novel cardiac biomarkers, growing demand for PoC testing), restraints (technical issues related to sample collection and storage, unfavorable regulatory processes and limited reimbursement structure), opportunities (ongoing research on novel cardiac biomarkers for cardiovascular diseases, emerging markets), and challenges (challenges associated with biomarker assay validation) influencing the growth of the cardiac marker testing market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the cardiac marker testing market.
  • Market Development: Comprehensive information about lucrative markets - the report analyzes the cardiac marker testing market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cardiac marker testing market

Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like F.Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (US), Siemens Healthineers AG (Germany), and Danaher Corporation (US).

Show more
Product Code: MD 4673

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKETS COVERED & REGIONAL SCOPE
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

  • 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS
  • 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS & STRATEGIC DEVELOPMENTS
  • 2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH
  • 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
  • 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

  • 3.1 CARDIAC MARKER TESTING MARKET OVERVIEW
  • 3.2 CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2026 VS. 2031
  • 3.3 CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2026 VS. 2031
  • 3.4 CARDIAC MARKER TESTING MARKET, BY INDICATION, 2026 VS. 2031
  • 3.5 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2026 VS. 2031
  • 3.6 CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2026 VS. 2031
  • 3.7 CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2026 VS. 2031
  • 3.8 CARDIAC MARKER TESTING MARKET, BY END USER, 2026 VS. 2031
  • 3.9 CARDIAC MARKER TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

4 MARKET OVERVIEW

  • 4.1 INTRODUCTION
  • 4.2 MARKET DYNAMICS
    • 4.2.1 DRIVERS
      • 4.2.1.1 Rising prevalence of cardiovascular diseases
      • 4.2.1.2 Increasing geriatric population and subsequent rise in heart conditions worldwide
      • 4.2.1.3 Rising clinical studies for identification of novel cardiac biomarkers
      • 4.2.1.4 Growing demand for PoC testing
    • 4.2.2 RESTRAINTS
      • 4.2.2.1 Technical issues related to sample collection and storage
      • 4.2.2.2 Unfavorable regulatory processes and limited reimbursement structure
    • 4.2.3 OPPORTUNITIES
      • 4.2.3.1 Ongoing research on novel cardiac biomarkers for cardiovascular diseases
      • 4.2.3.2 Emerging markets
    • 4.2.4 CHALLENGES
      • 4.2.4.1 Challenges associated with biomarker assay validation
  • 4.3 UNMET NEEDS & WHITE SPACES
    • 4.3.1 UNMET NEEDS IN CARDIAC MARKER TESTING MARKET
    • 4.3.2 WHITE SPACE OPPORTUNITIES
  • 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
    • 4.4.1 INTERCONNECTED MARKETS
    • 4.4.2 CROSS-SECTOR OPPORTUNITIES
  • 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
    • 4.5.1 KEY MOVES & STRATEGIC FOCUS

5 INDUSTRY TRENDS

  • 5.1 PORTER'S FIVE FORCES ANALYSIS
    • 5.1.1 THREAT OF NEW ENTRANTS
    • 5.1.2 THREAT OF SUBSTITUTES
    • 5.1.3 BARGAINING POWER OF BUYERS
    • 5.1.4 BARGAINING POWER OF SUPPLIERS
    • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.2 MACROECONOMIC INDICATORS
    • 5.2.1 INTRODUCTION
    • 5.2.2 GDP TRENDS & FORECAST
  • 5.3 SUPPLY CHAIN ANALYSIS
  • 5.4 VALUE CHAIN ANALYSIS
  • 5.5 ECOSYSTEM ANALYSIS
  • 5.6 PRICING ANALYSIS
    • 5.6.1 AVERAGE SELLING PRICE OF CARDIAC MARKER TESTING PRODUCTS, BY TYPE, 2024-2026
    • 5.6.2 AVERAGE SELLING PRICE OF CARDIAC MARKER TESTING PRODUCTS, BY KEY PLAYER, 2024-2026
    • 5.6.3 AVERAGE SELLING PRICE OF CARDIAC MARKER TESTING PRODUCTS, BY REGION, 2024-2026
  • 5.7 TRADE ANALYSIS
    • 5.7.1 IMPORT SCENARIO (HS CODE 3822)
    • 5.7.2 EXPORT SCENARIO (HS CODE 3822)
  • 5.8 KEY CONFERENCES & EVENTS, 2026-2027
  • 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.10 INVESTMENT & FUNDING SCENARIO
  • 5.11 CASE STUDY ANALYSIS
    • 5.11.1 CASE STUDY 1: IMPLEMENTATION OF HIGH-SENSITIVITY TROPONIN (HS-CTN) ASSAYS FOR RAPID MYOCARDIAL INFARCTION DIAGNOSIS
    • 5.11.2 CASE STUDY 2: USE OF BNP/NT-PROBNP TESTING FOR HEART FAILURE DIAGNOSIS AND MANAGEMENT
    • 5.11.3 CASE STUDY 3: USE OF HIGH-SENSITIVITY TROPONIN FOR LONG-TERM CARDIOVASCULAR RISK PREDICTION IN GENERAL POPULATION
  • 5.12 IMPACT OF 2025 US TARIFFS ON CARDIAC MARKER TESTING MARKET
    • 5.12.1 INTRODUCTION
    • 5.12.2 KEY TARIFF RATES
    • 5.12.3 PRICE IMPACT ANALYSIS
    • 5.12.4 IMPACT ON REGION
      • 5.12.4.1 North America
      • 5.12.4.2 Europe
      • 5.12.4.3 Asia Pacific
    • 5.12.5 IMPACT ON END-USE INDUSTRIES
      • 5.12.5.1 Hospital laboratories
      • 5.12.5.2 Reference laboratories
      • 5.12.5.3 Contract testing laboratories
      • 5.12.5.4 Academic institutes

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

  • 6.1 KEY EMERGING TECHNOLOGIES
    • 6.1.1 CHEMILUMINESCENCE IMMUNOASSAYS (CLIA)
    • 6.1.2 IMMUNOFLUORESCENCE ASSAYS (IFA)
    • 6.1.3 ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISA)
    • 6.1.4 LATERAL FLOW ASSAYS
  • 6.2 COMPLEMENTARY TECHNOLOGIES
    • 6.2.1 POC IMMUNOANALYZERS
    • 6.2.2 DIGITAL IMMUNOASSAY PLATFORMS
  • 6.3 TECHNOLOGY/PRODUCT ROADMAP
  • 6.4 PATENT ANALYSIS
    • 6.4.1 LIST OF MAJOR PATENTS
    • 6.4.2 LIST OF KEY PATENTS
  • 6.5 FUTURE APPLICATIONS
  • 6.6 IMPACT OF AI/GENERATIVE AI ON CARDIAC MARKER TESTING MARKET
    • 6.6.1 INTRODUCTION
    • 6.6.2 TOP USE CASES & MARKET POTENTIAL
    • 6.6.3 KEY COMPANIES IMPLEMENTING AI
    • 6.6.4 FUTURE OF AI

7 SUSTAINABILITY & REGULATORY LANDSCAPE

  • 7.1 REGIONAL REGULATIONS & COMPLIANCE
    • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.2 SUSTAINABILITY INITIATIVES
    • 7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN CARDIAC MARKER TESTING PRODUCTS
      • 7.2.1.1 Eco-friendly Initiatives
  • 7.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

  • 8.1 DECISION-MAKING PROCESS
  • 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
    • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 8.2.2 BUYING CRITERIA
  • 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
  • 8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
  • 8.5 MARKET PROFITABILITY
    • 8.5.1 REVENUE POTENTIAL
    • 8.5.2 COST DYNAMICS
    • 8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS

9 CARDIAC MARKER TESTING MARKET, BY PRODUCT

  • 9.1 INTRODUCTION
  • 9.2 REAGENTS & KITS
    • 9.2.1 RISING VOLUME OF DIAGNOSTIC TESTS TO DRIVE DEMAND FOR REAGENTS & KITS
  • 9.3 INSTRUMENTS
    • 9.3.1 EXPANDING DIAGNOSTIC INFRASTRUCTURE TO DRIVE MARKET GROWTH

10 CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY

  • 10.1 INTRODUCTION
  • 10.2 IMMUN0ASSAYS
    • 10.2.1 CHEMILUMINESCENCE
      • 10.2.1.1 High sensitivity, wide linear range, and good specificity to aid market growth
    • 10.2.2 IMMUNOFLUORESCENCE
      • 10.2.2.1 Advancements in fluorescence technologies to drive immunofluorescence adoption
    • 10.2.3 LATERAL FLOW IMMUNOASSAYS
      • 10.2.3.1 Increasing use in point-of-care settings to propel adoption
    • 10.2.4 ELISA
      • 10.2.4.1 Long shelf life and ease of use to propel growth
  • 10.3 CLINICAL CHEMISTRY
    • 10.3.1 COST-EFFECTIVENESS AND HIGH-THROUGHPUT TESTING TO SUSTAIN GROWTH IN CLINICAL CHEMISTRY MARKET

11 CARDIAC MARKER TESTING MARKET, BY INDICATION

  • 11.1 INTRODUCTION
  • 11.2 MYOCARDIAL INFARCTION
    • 11.2.1 RISING MYOCARDIAL INFARCTION BURDEN AND NEED FOR EARLY DIAGNOSIS TO DRIVE CARDIAC MARKER TESTING DEMAND
  • 11.3 CONGESTIVE HEART FAILURE
    • 11.3.1 INCREASING USE OF MULTIMARKER TESTING TO SUPPORT MARKET GROWTH
  • 11.4 ACUTE CORONARY SYNDROME
    • 11.4.1 INCREASING INCIDENCE OF RISK FACTORS ASSOCIATED WITH ACS TO DRIVE ADOPTION OF CARDIAC MARKERS
  • 11.5 ATHEROSCLEROSIS
    • 11.5.1 HIGH PREVALENCE OF ATHEROSCLEROSIS TO DRIVE MARKET
  • 11.6 ISCHEMIA
    • 11.6.1 INCREASE IN CARDIAC ISCHEMIA TO BOOST DEMAND FOR CARDIAC MARKER TESTS

12 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE

  • 12.1 INTRODUCTION
  • 12.2 TROPONIN I & T
    • 12.2.1 HIGH SENSITIVITY AND SPECIFICITY IN DETECTION OF CVD TO DRIVE MARKET
  • 12.3 CREATININE KINASE-MB
    • 12.3.1 POOR SPECIFICITY AND BRIEF ELEVATION DURATION TO HAMPER MARKET GROWTH
  • 12.4 BRAIN NATRIURETIC PEPTIDE
    • 12.4.1 USE OF BNP WITH OTHER CARDIAC MARKERS TO ENHANCE UTILIZATION
  • 12.5 MYOGLOBIN
    • 12.5.1 GROWING USE TO ASSESS PATIENTS WITH CHEST PAIN IN EMERGENCY DEPARTMENT SETTINGS TO BOOST GROWTH
  • 12.6 HOMOCYSTEINE
    • 12.6.1 RISK STRATIFICATION AND LONG-TERM CARDIOVASCULAR RISK ASSESSMENT TO DRIVE MARKET GROWTH
  • 12.7 HIGH-SENSITIVITY C-REACTIVE PROTEIN
    • 12.7.1 INCREASING INCIDENCE OF CARDIOVASCULAR DISEASES TO PROPEL ADOPTION
  • 12.8 OTHER CARDIAC BIOMARKERS

13 CARDIAC MARKER TESTING MARKET VOLUME ANALYSIS, BY BIOMARKER TYPE (NUMBER OF TESTS)

14 CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING

  • 14.1 INTRODUCTION
  • 14.2 LAB TESTS
    • 14.2.1 HIGH-SENSITIVITY, AUTOMATION, AND FLEXIBLE PROCUREMENT MODELS TO DRIVE LAB-BASED TESTING DOMINANCE
  • 14.3 POC TESTS
    • 14.3.1 RISING DEMAND FOR DECENTRALIZED HEALTHCARE SERVICES TO DRIVE MARKET

15 CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT

  • 15.1 INTRODUCTION
  • 15.2 SINGLEPLEX ASSAYS
    • 15.2.1 HIGH ACCURACY AND OPERATIONAL SIMPLICITY TO SUSTAIN SINGLEPLEX ASSAY DOMINANCE
  • 15.3 MULTIPLEX ASSAYS
    • 15.3.1 COMPREHENSIVE MULTI-BIOMARKER DETECTION AND RAPID DIAGNOSIS TO DRIVE MULTIPLEX ASSAY GROWTH

16 CARDIAC MARKER TESTING MARKET, BY END USER

  • 16.1 INTRODUCTION
  • 16.2 LABORATORY TESTING FACILITIES
    • 16.2.1 HOSPITAL LABORATORIES
      • 16.2.1.1 Growing focus on healthcare system to stimulate growth
    • 16.2.2 REFERENCE LABORATORIES
      • 16.2.2.1 Rising outsourcing and advanced testing capabilities to position reference laboratories as key growth drivers
    • 16.2.3 CONTRACT TESTING LABORATORIES
      • 16.2.3.1 Outsourced expertise and scalable testing capabilities to boost role of contract laboratories
  • 16.3 ACADEMIC INSTITUTES
    • 16.3.1 CONTINUOUS RESEARCH & DEVELOPMENT OF NOVEL BIOMARKERS TO DRIVE MARKET
  • 16.4 POINT-OF-CARE TESTING
    • 16.4.1 EARLY DETECTION AND LOWER TURNAROUND TIME TO BOOST MARKET

17 CARDIAC MARKER TESTING MARKET, BY REGION

  • 17.1 INTRODUCTION
  • 17.2 NORTH AMERICA
    • 17.2.1 US
      • 17.2.1.1 Growing support from NIH for development of novel cardiac biomarkers to drive market
    • 17.2.2 CANADA
      • 17.2.2.1 Government initiatives to support market growth
  • 17.3 EUROPE
    • 17.3.1 GERMANY
      • 17.3.1.1 Stringent regulations for food, pharmaceutical, and medical device industries to fuel growth
    • 17.3.2 UK
      • 17.3.2.1 Increasing cardiovascular patient volume to spur growth
    • 17.3.3 FRANCE
      • 17.3.3.1 Highly advanced and well-established healthcare system to drive demand for market
    • 17.3.4 ITALY
      • 17.3.4.1 Growing geriatric population and improved life expectancy to support market growth
    • 17.3.5 SPAIN
      • 17.3.5.1 Government efforts to improve health infrastructure to fuel demand
    • 17.3.6 REST OF EUROPE
  • 17.4 ASIA PACIFIC
    • 17.4.1 JAPAN
      • 17.4.1.1 Growing geriatric population and increasing incidence of chronic diseases to drive market
    • 17.4.2 CHINA
      • 17.4.2.1 Rising number of hospitals and increasing healthcare expenditure to boost adoption
    • 17.4.3 INDIA
      • 17.4.3.1 Infrastructural improvements to support growth
    • 17.4.4 AUSTRALIA
      • 17.4.4.1 Higher government healthcare expenditure to support market growth
    • 17.4.5 SOUTH KOREA
      • 17.4.5.1 Country's fast-aging demographic to drive market
    • 17.4.6 REST OF ASIA PACIFIC
  • 17.5 LATIN AMERICA
    • 17.5.1 BRAZIL
      • 17.5.1.1 Rising government support to boost adoption of market
    • 17.5.2 MEXICO
      • 17.5.2.1 Rising geriatric population to support market growth
    • 17.5.3 REST OF LATIN AMERICA
  • 17.6 MIDDLE EAST & AFRICA

18 COMPETITIVE LANDSCAPE

  • 18.1 INTRODUCTION
  • 18.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 18.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN CARDIAC MARKER TESTING MARKET
  • 18.3 REVENUE ANALYSIS, 2023-2025
  • 18.4 MARKET SHARE ANALYSIS, 2025
    • 18.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025
    • 18.4.2 US MARKET SHARE ANALYSIS, 2025
  • 18.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
    • 18.5.1 STARS
    • 18.5.2 EMERGING LEADERS
    • 18.5.3 PERVASIVE PLAYERS
    • 18.5.4 PARTICIPANTS
    • 18.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
      • 18.5.5.1 Company footprint
      • 18.5.5.2 Region footprint
      • 18.5.5.3 Product footprint
      • 18.5.5.4 Technology footprint
      • 18.5.5.5 Point of testing footprint
  • 18.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
    • 18.6.1 PROGRESSIVE COMPANIES
    • 18.6.2 RESPONSIVE COMPANIES
    • 18.6.3 DYNAMIC COMPANIES
    • 18.6.4 STARTING BLOCKS
    • 18.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
      • 18.6.5.1 Detailed list of key startups/SMEs
      • 18.6.5.2 Competitive benchmarking of startups/SMEs (1/2)
      • 18.6.5.3 Competitive benchmarking of startups/SMEs (2/2)
  • 18.7 COMPANY VALUATION & FINANCIAL METRICS
    • 18.7.1 FINANCIAL METRICS
    • 18.7.2 COMPANY VALUATION
  • 18.8 BRAND/PRODUCT COMPARISON
  • 18.9 COMPETITIVE SCENARIO
    • 18.9.1 PRODUCT APPROVALS
    • 18.9.2 DEALS

19 COMPANY PROFILES

  • 19.1 KEY PLAYERS
    • 19.1.1 F. HOFFMANN-LA ROCHE AG
      • 19.1.1.1 Business overview
      • 19.1.1.2 Products offered
      • 19.1.1.3 Recent developments
        • 19.1.1.3.1 Product approvals
        • 19.1.1.3.2 Deals
      • 19.1.1.4 MnM view
        • 19.1.1.4.1 Key strengths
        • 19.1.1.4.2 Strategic choices
        • 19.1.1.4.3 Weaknesses & competitive threats
    • 19.1.2 ABBOTT LABORATORIES
      • 19.1.2.1 Business overview
      • 19.1.2.2 Products offered
      • 19.1.2.3 MnM view
        • 19.1.2.3.1 Key strengths
        • 19.1.2.3.2 Strategic choices
        • 19.1.2.3.3 Weaknesses & competitive threats
    • 19.1.3 DANAHER CORPORATION
      • 19.1.3.1 Business overview
      • 19.1.3.2 Products offered
      • 19.1.3.3 MnM view
        • 19.1.3.3.1 Key strengths
        • 19.1.3.3.2 Strategic choices
        • 19.1.3.3.3 Weaknesses & competitive threats
    • 19.1.4 SIEMENS HEALTHINEERS AG
      • 19.1.4.1 Business overview
      • 19.1.4.2 Products offered
      • 19.1.4.3 MnM view
        • 19.1.4.3.1 Key strengths
        • 19.1.4.3.2 Strategic choices
        • 19.1.4.3.3 Weaknesses & competitive threats
    • 19.1.5 THERMO FISHER SCIENTIFIC
      • 19.1.5.1 Business overview
      • 19.1.5.2 Products offered
      • 19.1.5.3 MnM view
        • 19.1.5.3.1 Key strengths
        • 19.1.5.3.2 Strategic choices
        • 19.1.5.3.3 Weaknesses & competitive threats
    • 19.1.6 BIO-RAD LABORATORIES
      • 19.1.6.1 Business overview
      • 19.1.6.2 Products offered
    • 19.1.7 BIOMERIEUX SA
      • 19.1.7.1 Business overview
      • 19.1.7.2 Products offered
      • 19.1.7.3 Recent developments
        • 19.1.7.3.1 Deals
    • 19.1.8 BECTON, DICKINSON AND COMPANY
      • 19.1.8.1 Business overview
      • 19.1.8.2 Products offered
    • 19.1.9 DIASORIN SPA
      • 19.1.9.1 Business overview
      • 19.1.9.2 Products offered
    • 19.1.10 REVVITY
      • 19.1.10.1 Business overview
      • 19.1.10.2 Products offered
    • 19.1.11 TOSOH CORPORATION
      • 19.1.11.1 Business overview
      • 19.1.11.2 Products offered
    • 19.1.12 QUIDEL CORPORATION
      • 19.1.12.1 Business overview
      • 19.1.12.2 Products offered
      • 19.1.12.3 Recent developments
        • 19.1.12.3.1 Product approvals
        • 19.1.12.3.2 Deals
  • 19.2 OTHER PLAYERS
    • 19.2.1 LSI MEDIENCE CORPORATION (PHC HOLDINGS CORPORATION)
    • 19.2.2 RANDOX LABORATORIES
    • 19.2.3 GUANGZHOU WONDFO BIOTECH CO., LTD.
    • 19.2.4 BODITECH MED INC.
    • 19.2.5 BTNX INC.
    • 19.2.6 RESPONSE BIOMEDICAL
    • 19.2.7 ALFA SCIENTIFIC DESIGNS, INC.
    • 19.2.8 CTK BIOTECH
    • 19.2.9 CREATIVE DIAGNOSTICS
    • 19.2.10 LIFESIGN LLC
    • 19.2.11 DIASYS DIAGNOSTIC SYSTEMS GMBH
    • 19.2.12 ATLAS MEDICAL GMBH
    • 19.2.13 GETEIN BIOTECH INC.

20 RESEARCH METHODOLOGY

  • 20.1 RESEARCH DATA
    • 20.1.1 SECONDARY DATA
      • 20.1.1.1 List of secondary sources
      • 20.1.1.2 Key data from secondary sources
    • 20.1.2 PRIMARY DATA
      • 20.1.2.1 List of primary sources
      • 20.1.2.2 Key data from primary sources
      • 20.1.2.3 Key industry insights
      • 20.1.2.4 Breakdown of primary interviews
  • 20.2 MARKET SIZE ESTIMATION
    • 20.2.1 TOTAL MARKET SIZE: CARDIAC MARKER TESTING MARKET
    • 20.2.2 BOTTOM-UP APPROACH
      • 20.2.2.1 Approach 1: Revenue estimation of key players
      • 20.2.2.2 Approach 2: Study of annual reports and investor presentations
      • 20.2.2.3 Approach 3: Primary interviews
      • 20.2.2.4 Growth forecast
      • 20.2.2.5 CAGR projections
    • 20.2.3 TOP-DOWN APPROACH
  • 20.3 DATA TRIANGULATION
  • 20.4 RESEARCH ASSUMPTIONS
    • 20.4.1 STUDY-RELATED ASSUMPTIONS
    • 20.4.2 GROWTH RATE ASSUMPTIONS
  • 20.5 RESEARCH LIMITATIONS
  • 20.6 RISK ASSESSMENT

21 APPENDIX

  • 21.1 DISCUSSION GUIDE
  • 21.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 21.3 CUSTOMIZATION OPTIONS
  • 21.4 RELATED REPORTS
  • 21.5 AUTHOR DETAILS
Show more
Product Code: MD 4673

List of Tables

  • TABLE 1 CARDIAC MARKER TESTING MARKET: IMPACT OF PORTER'S FORCES
  • TABLE 2 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023-2030
  • TABLE 3 NORTH AMERICA: MACROECONOMIC INDICATORS
  • TABLE 4 EUROPE: MACROECONOMIC INDICATORS
  • TABLE 5 ASIA PACIFIC: MACROECONOMIC INDICATORS
  • TABLE 6 LATIN AMERICA: MACROECONOMIC INDICATORS
  • TABLE 7 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
  • TABLE 8 CARDIAC MARKER TESTING MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 9 AVERAGE SELLING PRICING OF CARDIAC MARKER TESTING PRODUCTS, BY TYPE, 2024-2026 (USD)
  • TABLE 10 AVERAGE SELLING PRICE OF CARDIAC MARKER TESTING PRODUCTS, BY KEY PLAYER, 2024-2026 (USD)
  • TABLE 11 AVERAGE SELLING PRICE OF CARDIAC MARKER TESTING PRODUCTS, BY REGION, 2024-2026 (USD)
  • TABLE 12 IMPORT DATA FOR HS CODE 3822 DIAGNOSTIC KITS & REAGENTS, BY COUNTRY, 2021-2025 (USD MILLION)
  • TABLE 13 EXPORT DATA FOR HS CODE 3822 DIAGNOSTIC KITS & REAGENTS, BY COUNTRY, 2021-2025 (USD MILLION)
  • TABLE 14 CARDIAC MARKER TESTING MARKET: KEY CONFERENCES & EVENTS, 2026-2027
  • TABLE 15 US-ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 16 KEY PATENTS IN CARDIAC MARKER TESTING MARKET, 2022-2026
  • TABLE 17 KEY COMPANIES IMPLEMENTING AI IN CARDIAC MARKER TESTING MARKET
  • TABLE 18 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 19 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 20 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 21 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 22 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%)
  • TABLE 24 KEY BUYING CRITERIA, BY END USER
  • TABLE 25 ADOPTION BARRIERS & INTERNAL CHALLENGES
  • TABLE 26 CARDIAC MARKER TESTING MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
  • TABLE 27 CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 28 SOME KEY COMPANIES PROVIDING CARDIAC MARKER TESTING REAGENTS & KITS
  • TABLE 29 CARDIAC MARKER TESTING REAGENTS & KITS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 30 NORTH AMERICA: CARDIAC MARKER TESTING REAGENTS & KITS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 31 EUROPE: CARDIAC MARKER TESTING REAGENTS & KITS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 32 ASIA PACIFIC: CARDIAC MARKER TESTING REAGENTS & KITS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 33 LATIN AMERICA: CARDIAC MARKER TESTING REAGENTS & KITS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 34 SOME KEY COMPANIES PROVIDING CARDIAC MARKER TESTING INSTRUMENTS
  • TABLE 35 CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 36 NORTH AMERICA: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 37 EUROPE: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 38 ASIA PACIFIC: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 39 LATIN AMERICA: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 40 CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 41 CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 42 CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 43 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 44 EUROPE: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 45 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 46 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 47 CARDIAC MARKER TESTING MARKET FOR CHEMILUMINESCENCE, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 48 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR CHEMILUMINESCENCE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 49 EUROPE: CARDIAC MARKER TESTING MARKET FOR CHEMILUMINESCENCE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 50 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR CHEMILUMINESCENCE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 51 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR CHEMILUMINESCENCE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 52 CARDIAC MARKER TESTING MARKET FOR IMMUNOFLUORESCENCE, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 53 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR IMMUNOFLUORESCENCE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 54 EUROPE: CARDIAC MARKER TESTING MARKET FOR IMMUNOFLUORESCENCE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 55 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR IMMUNOFLUORESCENCE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 56 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR IMMUNOFLUORESCENCE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 57 CARDIAC MARKER TESTING MARKET FOR LATERAL FLOW IMMUNOASSAYS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 58 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR LATERAL FLOW IMMUNOASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 59 EUROPE: CARDIAC MARKER TESTING MARKET FOR LATERAL FLOW IMMUNOASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 60 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR LATERAL FLOW IMMUNOASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 61 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR LATERAL FLOW IMMUNOASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 62 CARDIAC MARKER TESTING MARKET FOR ELISA, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 63 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR ELISA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 64 EUROPE: CARDIAC MARKER TESTING MARKET FOR ELISA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 65 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR ELISA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 66 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR ELISA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 67 CARDIAC MARKER TESTING MARKET FOR CLINICAL CHEMISTRY, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 68 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 69 EUROPE: CARDIAC MARKER TESTING MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 70 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 71 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 72 CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 73 CARDIAC MARKER TESTING MARKET FOR MYOCARDIAL INFARCTION, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 74 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR MYOCARDIAL INFARCTION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 75 EUROPE: CARDIAC MARKER TESTING MARKET FOR MYOCARDIAL INFARCTION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 76 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR MYOCARDIAL INFARCTION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 77 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR MYOCARDIAL INFARCTION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 78 CARDIAC MARKER TESTING MARKET FOR CONGESTIVE HEART FAILURE, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 79 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR CONGESTIVE HEART FAILURE , BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 80 EUROPE: CARDIAC MARKER TESTING MARKET FOR CONGESTIVE HEART FAILURE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 81 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR CONGESTIVE HEART FAILURE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 82 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR CONGESTIVE HEART FAILURE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 83 CARDIAC MARKER TESTING MARKET FOR ACUTE CORONARY SYNDROME, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 84 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR ACUTE CORONARY SYNDROME, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 85 EUROPE: CARDIAC MARKER TESTING MARKET FOR ACUTE CORONARY SYNDROME, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 86 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR ACUTE CORONARY SYNDROME, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 87 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR ACUTE CORONARY SYNDROME, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 88 CARDIAC MARKER TESTING MARKET FOR ATHEROSCLEROSIS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 89 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR ATHEROSCLEROSIS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 90 EUROPE: CARDIAC MARKER TESTING MARKET FOR ATHEROSCLEROSIS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 91 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR ATHEROSCLEROSIS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 92 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR ATHEROSCLEROSIS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 93 CARDIAC MARKER TESTING MARKET FOR ISCHEMIA, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 94 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR ISCHEMIA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 95 EUROPE: CARDIAC MARKER TESTING MARKET FOR ISCHEMIA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 96 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR ISCHEMIA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 97 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR ISCHEMIA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 98 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024-2031 (USD MILLION)
  • TABLE 99 CARDIAC MARKER TESTING MARKET FOR TROPONIN I & T, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 100 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR TROPONIN I & T, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 101 EUROPE: CARDIAC MARKER TESTING MARKET FOR TROPONIN I & T, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 102 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR TROPONIN I & T, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 103 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR TROPONIN I & T, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 104 CARDIAC MARKER TESTING MARKET FOR CREATININE KINASE-MB, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 105 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR CREATININE KINASE-MB, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 106 EUROPE: CARDIAC MARKER TESTING MARKET FOR CREATININE KINASE-MB, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 107 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR CREATININE KINASE-MB, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 108 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR CREATININE KINASE-MB, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 109 CARDIAC MARKER TESTING MARKET FOR BRAIN NATRIURETIC PEPTIDE, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 110 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR BRAIN NATRIURETIC PEPTIDE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 111 EUROPE: CARDIAC MARKER TESTING MARKET FOR BRAIN NATRIURETIC PEPTIDE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 112 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR BRAIN NATRIURETIC PEPTIDE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 113 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR BRAIN NATRIURETIC PEPTIDE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 114 CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 115 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 116 EUROPE: CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 117 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 118 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 119 CARDIAC MARKER TESTING MARKET FOR HOMOCYSTEINE, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 120 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR HOMOCYSTEINE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 121 EUROPE: CARDIAC MARKER TESTING MARKET FOR HOMOCYSTEINE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 122 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR HOMOCYSTEINE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 123 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR HOMOCYSTEINE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 124 CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 125 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 126 EUROPE: CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 127 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 128 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 129 CARDIAC MARKER TESTING MARKET FOR OTHER CARDIAC BIOMARKERS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 130 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR OTHER CARDIAC BIOMARKERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 131 EUROPE: CARDIAC MARKER TESTING MARKET FOR OTHER CARDIAC BIOMARKERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 132 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR OTHER CARDIAC BIOMARKERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 133 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR OTHER CARDIAC BIOMARKERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 134 US: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024-2031 (MILLION UNITS)
  • TABLE 135 CANADA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024-2031 (MILLION UNITS)
  • TABLE 136 GERMANY: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024-2031 (MILLION UNITS)
  • TABLE 137 UK: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024-2031 (MILLION UNITS)
  • TABLE 138 FRANCE: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024-2031 (MILLION UNITS)
  • TABLE 139 ITALY: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024-2031 (MILLION UNITS)
  • TABLE 140 SPAIN: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024-2031 (MILLION UNITS)
  • TABLE 141 CHINA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024-2031 (MILLION UNITS)
  • TABLE 142 JAPAN: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024-2031 (MILLION UNITS)
  • TABLE 143 INDIA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024-2031 (MILLION UNITS)
  • TABLE 144 BRAZIL: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024-2031 (MILLION UNITS)
  • TABLE 145 MEXICO: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024-2031 (MILLION UNITS)
  • TABLE 146 CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024-2031 (USD MILLION)
  • TABLE 147 CARDIAC MARKER TESTING MARKET FOR LAB TESTS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 148 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR LAB TESTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 149 EUROPE: CARDIAC MARKER TESTING MARKET FOR LAB TESTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 150 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR LAB TESTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 151 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR LAB TESTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 152 CARDIAC MARKER TESTING MARKET FOR POC TESTS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 153 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR POC TESTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 154 EUROPE: CARDIAC MARKER TESTING MARKET FOR POC TESTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 155 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR POC TESTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 156 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR POC TESTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 157 CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024-2031 (USD MILLION)
  • TABLE 158 CARDIAC MARKER TESTING MARKET FOR SINGLEPLEX ASSAYS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 159 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR SINGLEPLEX ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 160 EUROPE: CARDIAC MARKER TESTING MARKET FOR SINGLEPLEX ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 161 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR SINGLEPLEX ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 162 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR SINGLEPLEX ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 163 CARDIAC MARKER TESTING MARKET FOR MULTIPLEX ASSAYS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 164 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR MULTIPLEX ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 165 EUROPE: CARDIAC MARKER TESTING MARKET FOR MULTIPLEX ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 166 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR MULTIPLEX ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 167 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR MULTIPLEX ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 168 CARDIAC MARKER TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 169 CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 170 CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 171 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 172 EUROPE: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 173 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 174 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 175 CARDIAC MARKER TESTING MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 176 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 177 EUROPE: CARDIAC MARKER TESTING MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 178 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 179 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 180 CARDIAC MARKER TESTING MARKET FOR REFERENCE LABORATORIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 181 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 182 EUROPE: CARDIAC MARKER TESTING MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 183 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 184 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 185 CARDIAC MARKER TESTING MARKET FOR CONTRACT TESTING LABORATORIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 186 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR CONTRACT TESTING LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 187 EUROPE: CARDIAC MARKER TESTING MARKET FOR CONTRACT TESTING LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 188 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR CONTRACT TESTING LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 189 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR CONTRACT TESTING LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 190 CARDIAC MARKER TESTING MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 191 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 192 EUROPE: CARDIAC MARKER TESTING MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 193 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 194 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 195 CARDIAC MARKER TESTING MARKET FOR POINT-OF-CARE TESTING, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 196 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR POINT-OF-CARE TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 197 EUROPE: CARDIAC MARKER TESTING MARKET FOR POINT-OF-CARE TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 198 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR POINT-OF-CARE TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 199 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR POINT-OF-CARE TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 200 CARDIAC MARKER TESTING MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 201 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 202 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 203 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 204 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 205 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 206 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024-2031 (USD MILLION)
  • TABLE 207 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024-2031 (USD MILLION)
  • TABLE 208 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024-2031 (USD MILLION)
  • TABLE 209 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 210 NORTH AMERICA: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 211 US: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 212 US: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 213 US: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 214 US: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 215 US: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024-2031 (USD MILLION)
  • TABLE 216 US: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024-2031 (USD MILLION)
  • TABLE 217 US: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024-2031 (USD MILLION)
  • TABLE 218 US: CARDIAC MARKER TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 219 US: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 220 CANADA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 221 CANADA: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 222 CANADA: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 223 CANADA: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 224 CANADA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024-2031 (USD MILLION)
  • TABLE 225 CANADA: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024-2031 (USD MILLION)
  • TABLE 226 CANADA: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024-2031 (USD MILLION)
  • TABLE 227 CANADA: CARDIAC MARKER TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 228 CANADA: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 229 EUROPE: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 230 EUROPE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 231 EUROPE: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 232 EUROPE: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 233 EUROPE: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 234 EUROPE: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024-2031 (USD MILLION)
  • TABLE 235 EUROPE: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024-2031 (USD MILLION)
  • TABLE 236 EUROPE: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024-2031 (USD MILLION)
  • TABLE 237 EUROPE: CARDIAC MARKER TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 238 EUROPE: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 239 GERMANY: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 240 GERMANY: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 241 GERMANY: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 242 GERMANY: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 243 GERMANY: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024-2031 (USD MILLION)
  • TABLE 244 GERMANY: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024-2031 (USD MILLION)
  • TABLE 245 GERMANY: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024-2031 (USD MILLION)
  • TABLE 246 GERMANY: CARDIAC MARKER TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 247 GERMANY: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 248 UK: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 249 UK: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 250 UK: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 251 UK: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 252 UK: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024-2031 (USD MILLION)
  • TABLE 253 UK: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024-2031 (USD MILLION)
  • TABLE 254 UK: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024-2031 (USD MILLION)
  • TABLE 255 UK: CARDIAC MARKER TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 256 UK: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 257 FRANCE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 258 FRANCE: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 259 FRANCE: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 260 FRANCE: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 261 FRANCE: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024-2031 (USD MILLION)
  • TABLE 262 FRANCE: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024-2031 (USD MILLION)
  • TABLE 263 FRANCE: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024-2031 (USD MILLION)
  • TABLE 264 FRANCE: CARDIAC MARKER TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 265 FRANCE: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 266 ITALY: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 267 ITALY: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 268 ITALY: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 269 ITALY: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 270 ITALY: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024-2031 (USD MILLION)
  • TABLE 271 ITALY: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024-2031 (USD MILLION)
  • TABLE 272 ITALY: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024-2031 (USD MILLION)
  • TABLE 273 ITALY: CARDIAC MARKER TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 274 ITALY: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 275 SPAIN: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 276 SPAIN: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 277 SPAIN: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 278 SPAIN: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 279 SPAIN: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024-2031 (USD MILLION)
  • TABLE 280 SPAIN: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024-2031 (USD MILLION)
  • TABLE 281 SPAIN: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024-2031 (USD MILLION)
  • TABLE 282 SPAIN: CARDIAC MARKER TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 283 SPAIN: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 284 REST OF EUROPE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 285 REST OF EUROPE: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 286 REST OF EUROPE: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 287 REST OF EUROPE: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 288 REST OF EUROPE: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024-2031 (USD MILLION)
  • TABLE 289 REST OF EUROPE: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024-2031 (USD MILLION)
  • TABLE 290 REST OF EUROPE: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024-2031 (USD MILLION)
  • TABLE 291 REST OF EUROPE: CARDIAC MARKER TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 292 REST OF EUROPE: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 293 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 294 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 295 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 296 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 297 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 298 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024-2031 (USD MILLION)
  • TABLE 299 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024-2031 (USD MILLION)
  • TABLE 300 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024-2031 (USD MILLION)
  • TABLE 301 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 302 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 303 JAPAN: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 304 JAPAN: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 305 JAPAN: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 306 JAPAN: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 307 JAPAN: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024-2031 (USD MILLION)
  • TABLE 308 JAPAN: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024-2031 (USD MILLION)
  • TABLE 309 JAPAN: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024-2031 (USD MILLION)
  • TABLE 310 JAPAN: CARDIAC MARKER TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 311 JAPAN: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 312 CHINA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 313 CHINA: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 314 CHINA: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 315 CHINA: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 316 CHINA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024-2031 (USD MILLION)
  • TABLE 317 CHINA: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024-2031 (USD MILLION)
  • TABLE 318 CHINA: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024-2031 (USD MILLION)
  • TABLE 319 CHINA: CARDIAC MARKER TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 320 CHINA: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 321 INDIA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 322 INDIA: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 323 INDIA: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 324 INDIA: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 325 INDIA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024-2031 (USD MILLION)
  • TABLE 326 INDIA: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024-2031 (USD MILLION)
  • TABLE 327 INDIA: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024-2031 (USD MILLION)
  • TABLE 328 INDIA: CARDIAC MARKER TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 329 INDIA: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 330 AUSTRALIA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 331 AUSTRALIA: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 332 AUSTRALIA: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 333 AUSTRALIA: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 334 AUSTRALIA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024-2031 (USD MILLION)
  • TABLE 335 AUSTRALIA: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024-2031 (USD MILLION)
  • TABLE 336 AUSTRALIA: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024-2031 (USD MILLION)
  • TABLE 337 AUSTRALIA: CARDIAC MARKER TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 338 AUSTRALIA: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 339 SOUTH KOREA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 340 SOUTH KOREA: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 341 SOUTH KOREA: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAY, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 342 SOUTH KOREA: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 343 SOUTH KOREA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024-2031 (USD MILLION)
  • TABLE 344 SOUTH KOREA: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024-2031 (USD MILLION)
  • TABLE 345 SOUTH KOREA: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024-2031 (USD MILLION)
  • TABLE 346 SOUTH KOREA: CARDIAC MARKER TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 347 SOUTH KOREA: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 348 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 349 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 350 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 351 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 352 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024-2031 (USD MILLION)
  • TABLE 353 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024-2031 (USD MILLION)
  • TABLE 354 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024-2031 (USD MILLION)
  • TABLE 355 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 356 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 357 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 358 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 359 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 360 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 361 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 362 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024-2031 (USD MILLION)
  • TABLE 363 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024-2031 (USD MILLION)
  • TABLE 364 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024-2031 (USD MILLION)
  • TABLE 365 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 366 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 367 BRAZIL: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 368 BRAZIL: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 369 BRAZIL: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 370 BRAZIL: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 371 BRAZIL: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024-2031 (USD MILLION)
  • TABLE 372 BRAZIL: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024-2031 (USD MILLION)
  • TABLE 373 BRAZIL: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024-2031 (USD MILLION)
  • TABLE 374 BRAZIL: CARDIAC MARKER TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 375 BRAZIL: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 376 MEXICO: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 377 MEXICO: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 378 MEXICO: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 379 MEXICO: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 380 MEXICO: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024-2031 (USD MILLION)
  • TABLE 381 MEXICO: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024-2031 (USD MILLION)
  • TABLE 382 MEXICO: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024-2031 (USD MILLION)
  • TABLE 383 MEXICO: CARDIAC MARKER TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 384 MEXICO: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 385 REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 386 REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 387 REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAY, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 388 REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 389 REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024-2031 (USD MILLION)
  • TABLE 390 REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024-2031 (USD MILLION)
  • TABLE 391 REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024-2031 (USD MILLION)
  • TABLE 392 REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 393 REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 394 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 395 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 396 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET FOR IMMUNOASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 397 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 398 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2024-2031 (USD MILLION)
  • TABLE 399 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY POINT OF TESTING, 2024-2031 (USD MILLION)
  • TABLE 400 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY ASSAY FORMAT, 2024-2031 (USD MILLION)
  • TABLE 401 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 402 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 403 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN CARDIAC MARKER TESTING MARKET, JANUARY 2023-MARCH 2026
  • TABLE 404 CARDIAC MARKER TESTING MARKET: DEGREE OF COMPETITION
  • TABLE 405 CARDIAC MARKER TESTING MARKET: REGION FOOTPRINT
  • TABLE 406 CARDIAC MARKER TESTING MARKET: PRODUCT FOOTPRINT
  • TABLE 407 CARDIAC MARKER TESTING MARKET: TECHNOLOGY FOOTPRINT
  • TABLE 408 CARDIAC MARKER TESTING MARKET: POINT OF TESTING FOOTPRINT
  • TABLE 409 CARDIAC MARKER TESTING MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 410 CARDIAC MARKER TESTING MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2)
  • TABLE 411 CARDIAC MARKER TESTING MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2)
  • TABLE 412 CARDIAC MARKER TESTING MARKET: PRODUCT APPROVALS, JANUARY 2023-JANUARY 2026
  • TABLE 413 CARDIAC MARKER TESTING MARKET: DEALS, JANUARY 2023-JANUARY 2026
  • TABLE 414 F. HOFFMANN-LA ROCHE AG: COMPANY OVERVIEW
  • TABLE 415 F. HOFFMANN-LA ROCHE AG: PRODUCTS OFFERED
  • TABLE 416 F. HOFFMANN-LA ROCHE AG: PRODUCT APPROVALS, JANUARY 2023-JANUARY 2026
  • TABLE 417 F. HOFFMANN-LA ROCHE AG: DEALS, JANUARY 2023-JANUARY 2026
  • TABLE 418 ABBOTT LABORATORIES: COMPANY OVERVIEW
  • TABLE 419 ABBOTT LABORATORIES: PRODUCTS OFFERED
  • TABLE 420 DANAHER CORPORATION: COMPANY OVERVIEW
  • TABLE 421 DANAHER CORPORATION: PRODUCTS OFFERED
  • TABLE 422 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
  • TABLE 423 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED
  • TABLE 424 THERMO FISHER SCIENTIFIC: COMPANY OVERVIEW
  • TABLE 425 THERMO FISHER SCIENTIFIC: PRODUCTS OFFERED
  • TABLE 426 BIO-RAD LABORATORIES : COMPANY OVERVIEW
  • TABLE 427 BIO-RAD LABORATORIES : PRODUCTS OFFERED
  • TABLE 428 BIOMERIEUX SA : COMPANY OVERVIEW
  • TABLE 429 BIOMERIEUX SA : PRODUCTS OFFERED
  • TABLE 430 BIOMERIEUX SA: DEALS, JANUARY 2023-JANUARY 2026
  • TABLE 431 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
  • TABLE 432 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED
  • TABLE 433 DIASORIN SPA: COMPANY OVERVIEW
  • TABLE 434 DIASORIN SPA: PRODUCTS OFFERED
  • TABLE 435 REVVITY: COMPANY OVERVIEW
  • TABLE 436 REVVITY: PRODUCTS OFFERED
  • TABLE 437 TOSOH CORPORATION: COMPANY OVERVIEW
  • TABLE 438 TOSOH CORPORATION: PRODUCTS OFFERED
  • TABLE 439 QUIDEL CORPORATION: COMPANY OVERVIEW
  • TABLE 440 QUIDEL CORPORATION: PRODUCTS OFFERED
  • TABLE 441 QUIDEL CORPORATION: PRODUCT APPROVALS, JANUARY 2023-JANUARY 2026
  • TABLE 442 QUIDEL CORPORATION: DEALS, JANUARY 2023-JANUARY 2026
  • TABLE 443 LSI MEDIENCE CORPORATION (PHC HOLDINGS CORPORATION): COMPANY OVERVIEW
  • TABLE 444 RANDOX LABORATORIES: COMPANY OVERVIEW
  • TABLE 445 GUANGZHOU WONDFO BIOTECH CO., LTD.: COMPANY OVERVIEW
  • TABLE 446 BODITECH MED INC.: COMPANY OVERVIEW
  • TABLE 447 BTNX INC.: COMPANY OVERVIEW
  • TABLE 448 RESPONSE BIOMEDICAL: COMPANY OVERVIEW
  • TABLE 449 ALFA SCIENTIFIC DESIGNS, INC.: COMPANY OVERVIEW
  • TABLE 450 CTK BIOTECH: COMPANY OVERVIEW
  • TABLE 451 CREATIVE DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 452 LIFESIGN LLC: COMPANY OVERVIEW
  • TABLE 453 DIASYS DIAGNOSTIC SYSTEMS GMBH: COMPANY OVERVIEW
  • TABLE 454 ATLAS MEDICAL GMBH: COMPANY OVERVIEW
  • TABLE 455 GETEIN BIOTECH INC.: COMPANY OVERVIEW
  • TABLE 456 STUDY ASSUMPTIONS
  • TABLE 457 CARDIAC MARKER TESTING MARKET: RISK ASSESSMENT

List of Figures

  • FIGURE 1 CARDIAC MARKER TESTING MARKET SEGMENTATION & REGIONAL SCOPE
  • FIGURE 2 KEY INSIGHTS & MARKET HIGHLIGHTS
  • FIGURE 3 GLOBAL CARDIAC MARKER TESTING MARKET, 2024-2031
  • FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN CARDIAC MARKER TESTING MARKET, 2023-2025
  • FIGURE 5 DISRUPTIVE TRENDS IMPACTING GROWTH OF CARDIAC MARKER TESTING MARKET
  • FIGURE 6 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS IN CARDIAC MARKER TESTING MARKET, 2025
  • FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 8 RISING CASES OF CARDIOVASCULAR DISEASES TO DRIVE MARKET
  • FIGURE 9 REAGENTS & KITS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 10 IMMUNOASSAYS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 11 MYOCARDIAL INFARCTION SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 12 TROPONIN I & T SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 13 LAB TESTS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 14 SINGLEPLEX ASSAYS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 15 LABORATORY TESTING FACILITIES SEGMENT TO COMMAND LARGEST SHARE DURING FORECAST PERIOD
  • FIGURE 16 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 17 CARDIAC MARKER TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 18 CARDIAC MARKER TESTING MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 19 CARDIAC MARKER TESTING MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 20 CARDIAC MARKER TESTING MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 21 CARDIAC MARKER TESTING MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 22 CARDIAC MARKER TESTING MARKET: TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • FIGURE 23 NUMBER OF DEALS & FUNDING ACTIVITIES IN CARDIAC MARKER TESTING MARKET
  • FIGURE 24 PATENT ANALYSIS FOR CARDIAC MARKER TESTING, JANUARY 2016-DECEMBER 2025
  • FIGURE 25 MARKET POTENTIAL OF AI IN CARDIAC MARKER TESTING MARKET
  • FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER
  • FIGURE 27 KEY BUYING CRITERIA, BY END USER
  • FIGURE 28 NORTH AMERICA: CARDIAC MARKER TESTING MARKET SNAPSHOT
  • FIGURE 29 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET SNAPSHOT
  • FIGURE 30 REVENUE ANALYSIS OF KEY PLAYERS IN CARDIAC MARKER TESTING MARKET, 2023-2025 (USD MILLION)
  • FIGURE 31 CARDIAC MARKER TESTING MARKET SHARE ANALYSIS, 2025 (GLOBAL)
  • FIGURE 32 US: CARDIAC MARKER TESTING MARKET SHARE ANALYSIS, 2025
  • FIGURE 33 CARDIAC MARKER TESTING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
  • FIGURE 34 CARDIAC MARKER TESTING MARKET: COMPANY FOOTPRINT
  • FIGURE 35 CARDIAC MARKER TESTING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
  • FIGURE 36 EV/EBITDA OF KEY VENDORS
  • FIGURE 37 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 38 CARDIAC MARKER TESTING MARKET: BRAND/PRODUCT COMPARISON FOR CARDIAC MARKER TESTING
  • FIGURE 39 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2025)
  • FIGURE 40 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2025)
  • FIGURE 41 DANAHER CORPORATION: COMPANY SNAPSHOT (2025)
  • FIGURE 42 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2025)
  • FIGURE 43 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2025)
  • FIGURE 44 BIO-RAD LABORATORIES : COMPANY SNAPSHOT (2025)
  • FIGURE 45 BIOMERIEUX SA : COMPANY SNAPSHOT (2025)
  • FIGURE 46 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2025)
  • FIGURE 47 DIASORIN SPA: COMPANY SNAPSHOT (2024)
  • FIGURE 48 REVVITY: COMPANY SNAPSHOT (2025)
  • FIGURE 49 TOSOH CORPORATION: COMPANY SNAPSHOT (2025)
  • FIGURE 50 QUIDEL CORPORATION: COMPANY SNAPSHOT (2025)
  • FIGURE 51 RESEARCH DESIGN
  • FIGURE 52 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 53 TOP-DOWN APPROACH
  • FIGURE 54 DATA TRIANGULATION
  • FIGURE 55 PARAMETRIC ASSUMPTIONS
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!